Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

计划入组 45 人 · 首次发布于 2016 年 2 月 8 日

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

计划入组 16 人 · 首次发布于 2014 年 12 月 11 日

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

计划入组 23 人 · 首次发布于 2007 年 2 月 22 日

anti-BCMA CAR T-cell therapy (refractory or relapsed multiple myeloma)

anti-TriPRIL CAR T-cell therapy (relapsed or refractory multiple myeloma)

Anti-CD20 + anti-CD30 CAR T-cell therapy (relapsed/refractory lymphoma)

CARGO Therapeutics

United States

Viridian Metals Inc

United States

CELL AND GENE THERAPY CATAPULT

United Kingdom

Anova and Nouveau Biosciences Partner to Advance First-in-Human Trial of Nanomedicine Kromastat for T-Cell Lymphomas

Valemetostat Shows Promise in Relapsed/Refractory Peripheral T-Cell Lymphoma

FDA Approves Lymphir (denileukin diftitox-cxdl) for Relapsed/Refractory Cutaneous T-Cell Lymphoma